Lazard Asset Management
RPTX

Lazard Asset Management’s Repare Therapeutics RPTX Stock Holding History

Lazard Asset Management’s Portfolio RPTX Stock Details RPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-594
Closed -$2K – 2501
2024
Q3 		$2K Buy
594
+7
+1% +$23 ﹤0.01% 2099
2024
Q2 		$1K Buy
+587
New +$2.09K ﹤0.01% 2176
2024
Q1 		– Sell
-3,008
Closed -$21K – 2336
2023
Q4 		$21K Sell
3,008
-6,870
-70% -$38.4K ﹤0.01% 2053
2023
Q3 		$119K Buy
9,878
+7,136
+260% +$73.7K ﹤0.01% 1564
2023
Q2 		$28K Buy
2,742
+73
+3% +$752 ﹤0.01% 2032
2023
Q1 		$25K Sell
2,669
-5,119
-66% -$58.7K ﹤0.01% 2007
2022
Q4 		$114K Buy
+7,788
New +$116K ﹤0.01% 1475

Other funds holding RPTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Lazard Asset Management's RPTX Position: Q4 2024 in Review

Lazard Asset Management sold out of Repare Therapeutics (RPTX) in Q4 2024, closing a stake of 594 shares — an estimated $2K sold.

Lazard Asset Management first reported a position in RPTX in Q4 2022 and held it in 7 quarters. The position peaked at $119K in Q3 2023. 54 funds tracked by Wall St. Rank hold RPTX as of Q4 2024.

  • Lazard Asset Management reported no remaining Repare Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Lazard Asset Management sold 594 Repare Therapeutics shares in Q4 2024, an estimated $2K.
  • Lazard Asset Management first reported a position in Repare Therapeutics in Q4 2022 and held it in 7 quarters.
  • Lazard Asset Management's Repare Therapeutics position peaked at $119K in Q3 2023.
  • 54 funds tracked by Wall St. Rank held Repare Therapeutics as of Q4 2024.

Based on Lazard Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.